Skip to main content
. 2016 Dec 15;11(6):724–736. doi: 10.1093/ecco-jcc/jjw210

Figure 5.

Figure 5.

Therapeutic proof-of-concept in the SL1344:CBA/J mouse model. [A–F] In a pilot proof-of-concept experiment, SL1344-infected CBA mice were treated with 100 mg/kg/day CCG-203971 for 18 days, beginning 7 days before SL1344 infection. [A] Kaplan-Meier survival curve illustrating effects of CCG-203971 on animal survival. Anti-fibrotic efficacy of CCG-203971 as determined by expression of collagen I protein expression [B] normalised to glyceraldehyde 3-phosphate dehydrogenase [GAPDH] protein expression and fibrotic (COL1A1 [C] and IGF-1 [D]) and inflammatory (IL-1b [E] and IL-6 [F]) gene expression. *p < 0.05, **p < 0.01 compared with the uninfected control group. ###p < 0.001 compared with the SL1344-infected group.